Restless legs syndrome

Tired Legs? No Problem for PLAMECA!

Retrieved on: 
Wednesday, March 27, 2024
System, Weight gain, Inflammation, Twitch, Mayo Clinic, Restless legs syndrome, Sleep, Rest, Meal, Quality of life, Itch, Glass, Woman, Restless, Hesperidin, Water, Weather, Dietary supplement

FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- Tired legs syndrome is a common issue for many individuals. The restless, twitching symptoms can be distracting and uncomfortable and ultimately impact quality of life. PLAMECA's VENALIGHT PLUS CAPSULES were designed to restore circulation in the legs and eliminate the issue of restless legs.

Key Points: 
  • PLAMECA's VENALIGHT PLUS CAPSULES were designed to restore circulation in the legs and eliminate the issue of restless legs.
  • Also called Restless Legs Syndrome, tired legs is a health condition that occurs when an individual feels a sudden urge to move their legs while in a resting position.
  • "VENALIGHT PLUS is ideal for the treatment and prevention of tired legs," says PLAMECA's managing director, Óscar Fernández.
  • Tired legs are a common issue for many individuals, whether they develop due to warm weather, excessive weight gain, or simply standing for too long.

Los Angeles Center for Ear, Nose, Throat and Allergy Welcomes Sleep Medicine Specialist, Dr. Cyrus Haghighian, M.D. to Practice

Retrieved on: 
Thursday, February 1, 2024
Ear, Narcolepsy, Politics, University, Sleep, Patient, AASM, American Academy, Restless legs syndrome, Nursing

LOS ANGELES, Feb. 1, 2024 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Cyrus Haghighian to their practice. Dr. Haghighian is board certified with a robust educational background and extensive training in sleep conditions.

Key Points: 
  • LOS ANGELES, Feb. 1, 2024 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Cyrus Haghighian to their practice.
  • With a specialty in Sleep Medicine, Dr. Haghighian strives to help patients achieve better sleep and overall well-being.
  • Plus, his specialty in sleep medicine is a sought-after expertise that we are lucky to be able to offer."
  • To further advance his expertise he went on to pursue a fellowship in Sleep Medicine at the University of Southern California.

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Project Sleep Launches the Sleep Helpline™ to Provide Free and Personalized Support for People Facing Sleep Issues and Sleep Disorders

Retrieved on: 
Wednesday, December 6, 2023
Sleep, JD, Kleine–Levin syndrome, DSM-IV codes, REM, Narcolepsy, Sleep disorder, Patient, LOS, Obstructive sleep apnea, Idiopathic hypersomnia, Uncertainty, Sleep-related breathing disorder, Central sleep apnea, Eastern Time Zone, Caregiver, University, Upper airway resistance syndrome, Parasomnia, Diagnosis, Social, Doctor of Philosophy, Sleepwalking, Restless legs syndrome, Non-24-hour sleep–wake disorder, Pharmaceutical industry, Nursing

LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Project Sleep, a nonprofit dedicated to raising awareness of sleep health, sleep equity, and sleep disorders, is thrilled to announce the official launch of the Sleep Helpline™, a new, professionally-staffed national helpline providing timely and trusted resources to help individuals navigate sleep issues and sleep disorders at every step of the journey.

Key Points: 
  • "An estimated 50-70 million Americans live with a chronic sleep disorder, yet the majority are undiagnosed," said Julie Flygare , JD, President & CEO of Project Sleep.
  • "We know that the path to finding accurate sleep disorder diagnosis, treatment, and support is often long, lonely, and inefficient.
  • This is why the new Sleep Helpline will meet people where they are in moments of uncertainty, to provide free and personalized one-to-one support and resources."
  • Special thanks to Jazz Pharmaceuticals and Harmony Biosciences for generously providing sponsorship funding to support the development of Project Sleep's new Sleep Helpline to support millions of people facing sleep issues and sleep disorders.

BioAdaptives Targets Multi-Billion Dollar Sleep Market with SleepEZ™ Natural Supplement

Retrieved on: 
Thursday, October 26, 2023
Health, Human, Congress, OTC, Narcolepsy, Conditional sentence, Research, Sleep, Circadian rhythm, Immune system, Immunity, Risk, Animal, Sleep apnea, Insomnia, Restless legs syndrome, Pharmaceutical industry

LAS VEGAS, NV, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC:  BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, is targeting a multi-billion dollar industry with its popular, natural sleep supplement, SleepEZ™.

Key Points: 
  • LAS VEGAS, NV, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC:  BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, is targeting a multi-billion dollar industry with its popular, natural sleep supplement, SleepEZ™.
  • Sleep plays a vital role in good health, and this week, the world’s foremost experts in sleep medicine have converged in Rio de Janeiro at the World Sleep Congress to discuss the latest developments across clinical and basic sleep and circadian research.
  • Edward Jacobs, M.D., BioAdaptives CEO, said, “BioAdaptives’ mission is to improve health and wellness for humans and animals through natural plant-based products, and we are proud to be at the forefront of delivering a natural sleep supplement to people living with sleep disorders.
  • Our SleepEZ™ supplement works with the circadian rhythm to promote restful and sustained sleep without the morning hangover drowsiness, an unwanted feature of many sleep aids.

Ambulatory Polysomnography (PSG) Systems Market to Reach $570.7 Million, Globally, by 2031 at 6.0% CAGR: Allied Market Research

Retrieved on: 
Monday, May 15, 2023
PSG, Prevalence, Table, Coronavirus, COVID-19, Sleep, Restless legs syndrome, Narcolepsy, Sleep apnea, OSA, Obstructive sleep apnea, Insomnia, Polysomnography, Patient, Immune system, Growth, Diagnosis, PDF, Pharmaceutical industry

PORTLAND, Ore., May 15, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Ambulatory Polysomnography (PSG) Systems Market by Product (Up to 12 Channel PSG Systems, Up to 24 Channel PSG Systems, Up to 32 Channel PSG Systems, and Above 32 Channel PSG Systems), Application (Obstructive Sleep Apnea, Narcolepsy, Chronic Insomnia, and Others), End-user (Hospitals, Sleep Laboratories, and Home Care Settings), and Region (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2031." According to the report, the global ambulatory polysomnography (PSG) systems market generated $327 million in 2021, and is anticipated to generate $570.7 million by 2031, witnessing a CAGR of 6.0% from 2022 to 2031.

Key Points: 
  • The outbreak of the COVID-19 pandemic has had a huge impact on the growth of the global ambulatory polysomnography (PSG) systems market.
  • This affected the ambulatory polysomnography (PSG) systems market growth in the pandemic period.
  • The quantity of items available in the range of up to 24 channel PSG systems is bigger than the other 24 product categories, and hence, this sub-segment dominates the ambulatory polysomnography (PSG) systems market.
  • This reflects the increased prevalence of sleep disorders in China, and it also adds to the growth of the ambulatory polysomnography (PSG) systems market in China.

Ambulatory Polysomnography (PSG) Systems Market to Reach $570.7 Million, Globally, by 2031 at 6.0% CAGR: Allied Market Research

Retrieved on: 
Monday, May 15, 2023
PSG, Prevalence, Table, Coronavirus, COVID-19, Sleep, Restless legs syndrome, Narcolepsy, Sleep apnea, OSA, Obstructive sleep apnea, Insomnia, Polysomnography, Patient, Immune system, Growth, Diagnosis, PDF, Pharmaceutical industry

PORTLAND, Ore., May 15, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Ambulatory Polysomnography (PSG) Systems Market by Product (Up to 12 Channel PSG Systems, Up to 24 Channel PSG Systems, Up to 32 Channel PSG Systems, and Above 32 Channel PSG Systems), Application (Obstructive Sleep Apnea, Narcolepsy, Chronic Insomnia, and Others), End-user (Hospitals, Sleep Laboratories, and Home Care Settings), and Region (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2031." According to the report, the global ambulatory polysomnography (PSG) systems market generated $327 million in 2021, and is anticipated to generate $570.7 million by 2031, witnessing a CAGR of 6.0% from 2022 to 2031.

Key Points: 
  • The outbreak of the COVID-19 pandemic has had a huge impact on the growth of the global ambulatory polysomnography (PSG) systems market.
  • This affected the ambulatory polysomnography (PSG) systems market growth in the pandemic period.
  • The quantity of items available in the range of up to 24 channel PSG systems is bigger than the other 24 product categories, and hence, this sub-segment dominates the ambulatory polysomnography (PSG) systems market.
  • This reflects the increased prevalence of sleep disorders in China, and it also adds to the growth of the ambulatory polysomnography (PSG) systems market in China.

MCRA Assists Noctrix Health with FDA Marketing Authorization via the De Novo Pathway for the NTX100 Tonic Motor Activation System

Retrieved on: 
Monday, May 8, 2023
Communication, De novo, Marketing, Public, Food, Health, Quality of life, MCRA, Leg, Clinical trial, Digital health, Patient, Sleep disorder, Korea Disease Control and Prevention Agency, Quality assurance, RLS, Regulatory affairs, Restless legs syndrome, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medical device, Pharmaceutical industry, Biocompatibility, Neurology, Computer security

The NTX100 TOMAC System is an externally worn medical device that applies low-level electrical stimulation to peripheral nerve fibers in the leg to treat Restless Legs Syndrome (RLS).

Key Points: 
  • The NTX100 TOMAC System is an externally worn medical device that applies low-level electrical stimulation to peripheral nerve fibers in the leg to treat Restless Legs Syndrome (RLS).
  • Noctrix Health was granted the breakthrough device designation in May 2020 for use of the NTX100 TOMAC to treat drug-refractory RLS.
  • Our De Novo submission was supported by their wealth of expertise, allowing us to receive marketing authorization in a short period of time.
  • MCRA is pleased to continue supporting neurological innovation in the medical device industry by helping clients navigate global regulatory challenges.

Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023
Health, Biotechnology, Chapter Four, Influenza B virus, Central nervous system, Disease, Traumatic brain injury, Sympathetic nervous system, TB, Dizziness, A-Z, Stroke, Research, Directory, Weakness, Orientation, Headache, CNS, Chapter Three, Multiple sclerosis, Vertigo, Chapter One, Restless, Migraine, Chapter Two, Chapter Five, Chapter Six, Collection, Guillain–Barré syndrome, Peripheral neuropathy, Creutzfeldt–Jakob disease, Parkinson's disease, Amyotrophy, Spinal cord, ALS, Cerebral palsy, Hyperlink, Bacteria, Restless legs syndrome, Mycobacterium tuberculosis, Pharmaceutical industry, Music, Bank, Drug, Cryptocurrency, Medical device, Nausea, Haemophilus, Epilepsy, Pain, Neuralgia, Fibromyalgia, Paralysis, Stuttering, Meningitis

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Key Points: 
  • Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
  • Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016.
  • Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.